Detalhe da pesquisa
1.
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Ann Oncol
; 32(2): 269-278, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33130216
2.
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Ann Oncol
; 31(5): 619-625, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32205016
3.
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Ann Oncol
; 29(9): 1918-1925, 2018 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30016392
4.
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
Pediatr Blood Cancer
; 64(6)2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27905678
5.
Phase I trial outcomes in older patients with advanced solid tumours.
Br J Cancer
; 114(3): 262-8, 2016 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-26757260
6.
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Br J Cancer
; 113(11): 1541-7, 2015 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26554652
7.
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.
Ann Oncol
; 26(7): 1504-10, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25908604
8.
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
ESMO Open
; 9(4): 102254, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38387109
9.
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.
Br J Cancer
; 107(7): 1093-9, 2012 Sep 25.
Artigo
Inglês
| MEDLINE | ID: mdl-22935583
10.
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.
Br J Cancer
; 107(11): 1797-800, 2012 Nov 20.
Artigo
Inglês
| MEDLINE | ID: mdl-23099802
11.
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
Ann Oncol
; 23(8): 1968-1973, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22408187
12.
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
Oncology
; 83(4): 177-82, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22889980
13.
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Br J Cancer
; 103(8): 1149-53, 2010 Oct 12.
Artigo
Inglês
| MEDLINE | ID: mdl-20842130
14.
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
Br J Cancer
; 100(9): 1373-8, 2009 May 05.
Artigo
Inglês
| MEDLINE | ID: mdl-19401696
15.
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Clin Oncol (R Coll Radiol)
; 30(3): 185-191, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29224898
16.
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Clin Transl Radiat Oncol
; 12: 16-20, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-30073210
17.
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Breast
; 16(4): 420-4, 2007 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-17379519
18.
Hsp90 inhibitors in the clinic.
Handb Exp Pharmacol
; (172): 331-58, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-16610366
19.
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Oncogene
; 19(36): 4125-33, 2000 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-10962573
20.
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Clin Oncol (R Coll Radiol)
; 12(3): 182-7, 2000.
Artigo
Inglês
| MEDLINE | ID: mdl-10942336